ArticleCureus2024
Systemic Lupus Erythematosus Presenting With Cold-Antibody Autoimmune Hemolysis and Nephritis: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder that presents with a wide array of clinical features, including autoimmune hemolysis and nephritis. Autoimmune hemolysis in SLE is typically linked to warm antibodies, but the occurrence of cold agglutinin syndrome (CAS), driven by cold-reactive antibodies, is exceptionally rare. Lupus nephritis (LN) is among the most severe complications of SLE, characterized by immune complex-mediated glomerulonephritis, which often leads to considerable morbidity and mortality. Nephritis in SLE is a major indicator of chronic kidney disease, with many patients experiencing progressive renal damage over time. Early diagnosis and individualized treatment approaches are crucial for effectively managing these intertwined conditions. This case report presents a distinct clinical scenario involving a 53-year-old Hispanic female diagnosed with SLE, who concurrently presented with CAS and nephritis. The patient's initial symptoms included chest pain, severe macrocytic anemia, elevated creatinine levels, and evidence of active hemolysis. CAS was diagnosed through a positive direct antiglobulin test for C3d and elevated cold agglutinin titers. Further comprehensive assessments revealed dysgammaglobulinemia, hypocomplementemia, and positive anti-Ro antibodies, with a renal biopsy confirming LN (ISN/RPS Class IV and Class V). The patient exhibited a favorable response to a treatment regimen comprising high-dose steroids and anti-CD20 therapy, resulting in the complete cessation of hemolysis and a >50% decrease in proteinuria after six months. This case underscores the rarity of CAS in the context of SLE, particularly when coupled with nephritis, and highlights the need for tailored treatment strategies. Anti-CD20 therapy, as used in primary CAS management, emerges as a promising option for this unique presentation, offering insights into the complex interplay of autoimmune conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.